frost & sullivan cancer therapies analyst briefing

Cancer Therapies: Getting Targeted and More Personalized

Sangeetha Prabakar, Industry Analyst

Technical Insights, Healthcare

9th September 2008

2

Scope of the Analyst Briefing

� An overview of cancer therapies

� Emerging trends in cancer therapies

� Overview of the factors influencing the future of cancer therapies

� Key opportunities for cancer research

� Drivers, restraints and challenges affecting cancer therapies

� Technology road map

� Noteworthy technologies and products

3

Areas of Major Advances

Nanotechnology

4

Diagnostics

Companion Diagnostics

�Prognosis

�Real Time Screening

�Drug Toxicity

�Drug Response Monitoring

�Prediction of Recurrence

�Pharmacogenomic Studies

Microarrays

5

Therapeutics

Targeted Therapy

�Monoclonal Antibodies

�Enzyme Inhibitors

�Proteasome Inhibitors

�Angiogenesis Inhibitors

6

Drug Delivery

Targeted Delivery

�Liposomes

�Nanoparticles

�Nanodrug Implants

�Polymer Drug Conjugates

7

One drug for a single phenotype

One drug for a specific

population

Personalized care – Patient specific drug

cocktails

Personalized care – one pill for individual

patient.

Future Paradigm of Cancer Care

Molecular DiagnosticsMicroarrays

Targeted TherapiesNanotechnology

Drug Delivery Technologies

Low HighMedium

8

Future Economic Trends in Cancer Care

Molecular Profiling

Molecular Phenotype

Tumor Genotype

Tumor Subtype

Disease Stage

Personalized Medicine

9

Growth Drivers for Cancer Drugs

10

Inadequate Data on Cancer Subtypes

Inadequate Data on Cancer Subtypes

Side Effects of Chemotherapy

Side Effects of Chemotherapy

Complicated Nature of

Chemotherapy

Complicated Nature of

Chemotherapy

Inherent Features of

Cancer Cells Complicate Drug Targeting

Inherent Features of

Cancer Cells Complicate Drug Targeting

Poor Target Specificity/Poor Drug

Solubility

Poor Target Specificity/Poor Drug

Solubility

Multiple Drug ResistanceMultiple Drug Resistance

Insurance/High Costs/Tough Regulatory

Environment

Insurance/High Costs/Tough Regulatory

Environment

Expiring Patent/Generic Threat

Expiring Patent/Generic Threat

Need for Regionalization of Clinical Trials

Need for Regionalization of Clinical Trials

Growth Restraining Factors for Anticancer Drugs

Growth Restraining Factors for Anticancer Drugs

11

Emerging Cancer Research Opportunities

12

Key Players and Their Innovations

13

Your Feedback is Important to Us

Growth Forecasts?

Competitive Structure?

Emerging Trends?

Strategic Recommendations?

Other?

Please inform us by taking our survey.

What would you like to see from Frost & Sullivan?

14

For Additional Information

• To leave a comment, ask the analyst a question, or receive the

free audio segment that accompanies this presentation, please contact Stephanie Ochoa, Social Media Manager at (210) 247-

2421, via email, analystbriefings@frost.com, or on Twitter at

http://twitter.com/stephanieochoa.